IMMUNOHISTOCHEMICAL DETECTION OF CEA AND CA 15-3 IN BREAST-CANCER - RELATION TO SERUM LEVELS AND PROGNOSTIC FACTORS

被引:0
|
作者
WEIKEL, W
KLEINMANN, A
BECK, T
MITZE, M
MOBUS, V
KREIENBERG, R
机构
关键词
BREAST CANCER; IMMUNOHISTOCHEMISTRY; TUMOR MARKER; CEA-CA-15-3;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In human breast cancer immunohistochemical detection of CEA and CA 15-3 was compared to the serum levels to these antigens. A significant correlation between immunohistochemical and serological positivity was found in 155 cases of CEA determination. In 159 cases of CA 15-3 analysis, a significant correlation between negative immunohistochemistry and positive serologic detection and vice versa was obtained. Concerning CEA, no correlation was found for immunohistochemical as well as serological analysis between stage of disease, lymphatic node involvement, histological grading, histological typing, immunohistochemical and biochemical hormone receptor assay., growth fraction (Ki-67), and NEU-protein overexpression. A clinical not significant trend was found towards better prognosis of serologically positive cases with respect to survival period and recurrence free interval. Concerning CA 15-3, in the same way no correlation was found with the mentioned prognostic factors except for a correlation of serum levels with the tumor mass. Patients with positive immunohistochemical or negative serological expression of CA 15-3 indicated a not significant trend towards better prognosis.
引用
收藏
页码:178 / 186
页数:9
相关论文
共 50 条
  • [41] CEA and CA 15-3 in invasive breast carcinoma
    Prtenjak, G
    Pap, D
    CLINICA CHIMICA ACTA, 2005, 355 : S435 - S436
  • [42] Comparison of serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of metastases and serum levels at the time of first diagnosis
    Dede, D. Sener
    Aksoy, S.
    Bulut, N.
    Dizdar, O.
    Arik, Z.
    Gullu, I.
    Ozisik, Y.
    Altundag, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer
    Eskelinen, M
    Kataja, V
    Hamalainen, E
    Kosma, VM
    Penttila, I
    Alhava, E
    ANTICANCER RESEARCH, 1997, 17 (2B) : 1231 - 1234
  • [44] CA 15-3 SERUM LEVELS IN OVARIAN-CANCER
    SCAMBIA, G
    PANICI, PB
    BAIOCCHI, G
    PERRONE, L
    GREGGI, S
    DIROBERTO, P
    MANCUSO, S
    ONCOLOGY, 1988, 45 (03) : 263 - 267
  • [45] Clinical value of TPS, CEA and CA 15-3 in breast cancer patients
    Blijlevens, NMA
    Oosterhuis, WP
    Oosten, HR
    Mulder, NH
    ANTICANCER RESEARCH, 1995, 15 (6B) : 2711 - 2716
  • [46] CEA, CA 15-3 and MCA: Comparative clinical relevance in breast cancer
    Bremer, K
    Micus, S
    Bremer, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1255 - 1255
  • [47] Comparison of the clinical relevance of CEA, CA 15-3 and MCA in breast cancer
    Bremer, K
    Micus, S
    Bremer, G
    Eberhard, A
    ONKOLOGIE, 1996, 19 (02): : 170 - 174
  • [48] Association of CA 15-3 and CEA with Liver Metastases in Patients with Breast Cancer
    Yazdani, Akram
    Akbari, Hossein
    CURRENT CANCER THERAPY REVIEWS, 2020, 16 (04) : 332 - 336
  • [49] USE OF CEA, CA 15-3 AND SIALIC-ACID IN EVALUATING THE CLINICAL COURSE OF BREAST-CANCER PATIENTS
    DNISTRIAN, AM
    GREENBERG, EJ
    SCHWARTZ, D
    SMITH, C
    SCHWARTZ, MK
    CLINICAL CHEMISTRY, 1989, 35 (06) : 1080 - 1080
  • [50] CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer
    Svobodova, Sarka
    Kucera, Radek
    Fiala, Ondrej
    Karlikova, Marie
    Narsanska, Andrea
    Zednikova, Ilona
    Treska, Vladislav
    Slouka, David
    Rousarova, Milena
    Topolcan, Ondrej
    Finek, Jindrich
    ANTICANCER RESEARCH, 2018, 38 (01) : 465 - 469